IDEXX Laboratories Surges to 196th in Trading Volume with $421 Million Turnover

On March 27, 2025, IDEXX Laboratories (IDXX) saw a significant increase in trading volume, with a turnover of $421 million, marking a 32.37% rise from the previous day. This surge placed IDEXX at the 196th position in terms of trading volume for the day. The stock price of IDEXX rose by 1.16%, marking the second consecutive day of gains, with a total increase of 1.17% over the past two days.

IDEXX Laboratories has a market capitalization of approximately $34.24 billion, with an enterprise value of $34.93 billion. The company's next estimated earnings date is April 30, 2025, before the market opens. As of the latest data, IDEXX has 81.04 million shares outstanding, with a slight decrease of 0.87% over the past year. Institutional investors hold 90.81% of the shares, while insiders own 0.98%.

The company's financial health is robust, with a current ratio of 1.31 and a debt-to-equity ratio of 0.62. The return on equity (ROE) stands at 57.66%, and the return on invested capital (ROIC) is 28.97%. In the past 12 months, IDEXX generated $3.90 billion in revenue and $887.87 million in profits, with earnings per share (EPS) at $10.67. The company's operating cash flow was $929.00 million, with a free cash flow of $808.08 million.

Analysts have given IDEXX an average rating of "Buy," with an average price target of $533.75, representing a 26.32% increase from the current price. The consensus rating among analysts is also "Buy," with an average price target of $533.75. The company's revenue growth forecast for the next five years is 8.10%, and the EPS growth forecast is 12.68%.